Literature DB >> 10958596

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.

J Vuky1, J McCaffrey, M Ginsberg, T Mariani, D F Bajorin, G J Bosl, R J Motzer.   

Abstract

Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10958596     DOI： 10.1023/a:1006434008357

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  9 in total

Review 1.  The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent.

Authors:  R C Jackson; J S Sebolt; J L Shillis; W R Leopold
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

2.  High-dose chemotherapy for germ cell tumors (GCT): Memorial Sloan Kettering Cancer Center.

Authors:  R J Motzer
Journal:  Bone Marrow Transplant       Date:  1996-09       Impact factor: 5.483

Review 3.  Testicular germ-cell cancer.

Authors:  G J Bosl; R J Motzer
Journal:  N Engl J Med       Date:  1997-07-24       Impact factor: 91.245

4.  Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.

Authors:  J S Sebolt; S V Scavone; C D Pinter; K L Hamelehle; D D Von Hoff; R C Jackson
Journal:  Cancer Res       Date:  1987-08-15       Impact factor: 12.701

5.  Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.

Authors:  J A McCaffrey; M Mazumdar; D F Bajorin; G J Bosl; V Vlamis; R J Motzer
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

Review 6.  Current status of pyrazoloacridine as an anticancer agent.

Authors:  A A Adjei
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

Authors:  P LoRusso; B J Foster; E Poplin; J McCormick; M Kraut; L Flaherty; L K Heilbrun; M Valdivieso; L Baker
Journal:  Clin Cancer Res       Date:  1995-12       Impact factor: 12.531

8.  Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

Authors:  E K Rowinsky; D A Noe; L B Grochow; S E Sartorious; M K Bowling; T L Chen; B G Lubejko; S H Kaufmann; R C Donehower
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

9.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544
  9 in total
  1 in total

1.  Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.

Authors:  Bhuvaneswari Ramaswamy; Ewa Mrozek; John Philip Kuebler; Tanios Bekaii-Saab; Eric H Kraut
Journal:  Invest New Drugs       Date:  2009-10-21       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.